Skip to content

Bicara Therapeutics BCAX Payments to Acquire Property, Plant, and Equipment

Payments to Acquire Property, Plant, and Equipment at other companies

Amgen logo
AmgenAMGN
Summit Therapeutics logo
Summit TherapeuticsSMMT

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.68B+81.4%

Returns & leverage

See full
Return on equity-32.3%
Debt / equity0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's payments to acquire property, plant, and equipment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bicara Therapeutics's payments to acquire property, plant, and equipment?
Bicara Therapeutics (BCAX) reported payments to acquire property, plant, and equipment of $60K in Q1 2026.
What does payments to acquire property, plant, and equipment mean?
Represents capital expenditures directed toward the acquisition or improvement of physical assets such as laboratory equipment or infrastructure. This metric highlights the company's investment in the tangible assets necessary to support its clinical development pipeline.